NAD+

Evidence

NAD+

Cellular Energy • Redox Metabolism • Mitochondrial Cofactor Research

At a Glance

What is NAD+?

NAD+ stands for:

Nicotinamide Adenine Dinucleotide It is a molecule naturally found in almost every cell in the body .

NAD+ is essential for normal cellular metabolism.

One of its most important jobs is helping the body turn nutrients into usable cellular energy .

It also plays a role in:

• redox chemistry

• DNA repair

• cellular stress responses

• sirtuin activity

• other NAD-dependent enzymes

NAD+ is not a peptide, hormone or stimulant .

It is a naturally occurring:

coenzyme

How well studied is it?

NAD+ biology is extremely well understood. NAD+ injections are much less studied.

This distinction matters.

Scientists know a great deal about:

• what NAD+ does inside cells

• NAD+/NADH chemistry

• how the body makes and recycles NAD+

• enzymes that use NAD+

• NAD+ precursors such as NR and NMN

But that does not mean injecting NAD+ has equally strong clinical evidence.

Direct NAD+ administration has mainly been studied through:

• small IV studies

• short human metabolism studies

• early tolerability research

• very small preliminary IM and SC exposure studies

A 2026 preliminary safety analysis reported small human groups receiving:

100 mg NAD+

by:

• IM

• SC

• IV-push

on:

3 consecutive days This is important because it gives us early controlled human exposure through IM and SC routes.

But it does not prove those doses provide clinical benefits.

Evidence level Basic NAD+ biology: Very strong Human NAD+ metabolism research: Strong Direct IV NAD+ research: Limited but real Direct IM/SC human research: Very early Energy / fatigue treatment evidence: Limited Anti-aging evidence from injections: Unproven Community injection protocols: Common but mostly practice-derived

What may it help with?

Strong biological evidence

Cellular Energy Metabolism

NAD+ is required for normal energy metabolism.

It helps the body process:

• carbohydrates

• fats

• amino acids

and turn them into usable cellular energy .

Important NAD+ being necessary for energy production does not automatically mean:

injecting more NAD+ gives a healthy person more energy .

Those are two different claims.

Redox Balance

NAD+ and NADH work together as part of a redox system.

Simple version NAD+ accepts electrons → becomes NADH and:

NADH gives up electrons → becomes NAD+ The body constantly cycles between these forms.

This process is central to normal metabolism.

NAD-Dependent Cell Signaling

NAD+ is also used by enzymes including:

• sirtuins

• PARPs

• CD38-related enzymes

These are involved in things such as:

• DNA repair

• metabolism

• cellular stress responses

• gene regulation

Direct Human NAD+ Research

Direct IV NAD+ has been shown to enter human metabolism.

In a 2019 pilot study , NAD+ was infused at:

3 μmol/min for:

6 hours Researchers found that infused NAD+ was rapidly removed from the blood early in the infusion and was then processed into related metabolites.

What This Supports Injected or infused NAD+:

does enter and affect human NAD-related metabolism.

What It Does Not Prove It does not prove that NAD+ infusion:

• treats fatigue

• improves memory

• reverses aging

• causes fat loss

• improves sports performance

• treats addiction

• repairs mitochondria

in otherwise healthy people.

What has it NOT been proven to help with?

Direct NAD+ injections have not been convincingly established as treatments for:

• aging

• longevity

• general chronic fatigue

• bodybuilding

• muscle growth

• fat loss

• athletic performance

• brain fog

• depression

• hangovers

• alcohol detoxification

• liver detoxification

• opioid or substance-use disorder

• GLP-1-related fatigue

• mitochondrial “rejuvenation”

• preventing age-related disease

• DNA repair as a measurable clinical outcome

NAD+ is involved in many of these biological systems.

That does not prove injecting extra NAD+ produces a meaningful treatment effect.

Human Clinical Research

Human research has used very different schedules.

Examples include:

• continuous IV infusion over 6 hours

• 500 mg IV on four consecutive days

• 100 mg NAD+ by IM, SC or IV-push over three consecutive days in a small preliminary

analysis There is therefore:

no single clinically established NAD+ injection frequency for general wellness.

Community

IM Commonly:

2–3 times weekly SC Ranges from:

several times per week to:

daily depending on the protocol.

Best-Supported Frequency?

Unknown Human research does not show that any of these is clearly better:

• daily SC

• 3x-weekly IM

• weekly IM

• monthly IV

for general metabolic health.

Clinical Research

There is no established requirement to take NAD+:

• in the morning

• at night

• fasted

• before exercise

• after exercise

• with carbohydrates

Community

Morning use is common because NAD+ is marketed for energy and some users describe feeling more alert.

That remains:

community preference rather than a proven timing rule.

Evidence verdict Morning required: No Night required: No Fasted required: No Pre-workout required: No With food required: No

Clinical Research

There is no universal NAD+ treatment cycle.

Human direct-NAD+ studies have used:

• one prolonged IV exposure

• several consecutive treatment days

• short experimental protocols

Community

Common schedules include:

• short IV “loading” series

• 8–16 weeks of SC injections

• intermittent IM injections

• weekly maintenance use

Does NAD+ Need to Be Cycled?

No receptor-reset cycle has been established.

NAD+ is not a conventional receptor agonist.

There is no established reason for:

• 5 days on / 2 days off

• 8 weeks on / 4 weeks off

• 12-week receptor resets

• mandatory washouts

Expected Results Timeline

Human Clinical Research

During IV Administration NAD+ enters human metabolism immediately after administration.

But in the 2019 IV study , circulating NAD+ did not simply keep building up in the blood.

It was rapidly being:

• removed

• broken down

• recycled

• converted into related metabolites

Important A biochemical change is not the same thing as :

feeling more energetic.

Clinical Benefit Timeline

Not established There is no strong human clinical evidence showing a predictable timeline such as:

Day 1: more energy Week 1: better thinking Week 2: improved mitochondria Week 4: better body composition from direct NAD+ injections.

Those should not be presented as clinical facts.

Community-Reported Timeline

Community sources often describe effects such as:

• energy

• alertness

• recovery

• general wellness

within:

hours to days of IV or injected NAD+.

Longer protocols describe changes over several weeks.

Important These remain:

anecdotal reports Best T op-Card Wording Clinical: NAD+ is processed rapidly after administration, but there is no established timeline for meaningful energy , wellness or anti-aging benefits.

Community-reported: some people describe subjective effects within the same day or during the first several treatments, but these experiences have not been established as controlled clinical outcomes.

Regulatory Status at a Glance

Is NAD+ Naturally Present in the Body?

Yes FDA-Approved NAD+ Injection for Energy or Anti-Aging?

No FDA-Approved Wellness Protocol?

No Do Compounded NAD+ Injections Exist?

Yes But compounded products are:

not FDA-approved NAD+ drugs FDA has also raised concerns about the ingredients and manufacturing quality used in some compounded injectable NAD+ products.

Important 2026 Regulatory Update

In a January 2026 warning letter to a registered outsourcing facility , FDA said NAD+ did:

not appear on the 503B Bulks List and that the cited NAD+ products therefore did not qualify for the relevant 503B compounding exemptions.

Important Do not simplify this to:

“ All NAD+ compounding is illegal.”

That is too broad.

The rules depend on:

• the type of compounding facility

• the regulatory pathway

• the exact substance

• the specific product

• applicable compounding law

Better Wording There is no FDA-approved NAD+ injection for wellness or anti-aging. FDA has also raised regulatory and product-quality concerns involving some compounded NAD+ injectables.

Bottom Line

NAD+ itself is one of the most important and best-established molecules in cellular metabolism. Injecting NAD+ is a much less certain question.

What is firmly established:

• NAD+ naturally exists in cells

• it is essential for energy metabolism

• it participates in redox chemistry

• many important enzymes use it

• directly administered NAD+ enters human metabolism

What is not firmly established :

• the best injection dose

• the best route

• the best frequency

• anti-aging benefit

• general fatigue treatment

• cognitive enhancement

• fat-loss benefit

• athletic-performance benefit

• GLP-1 fatigue prevention

• long-term IM/SC safety

Community protocols often use:

50–200 mg IM several times per week or:

50–100 mg SC with schedules ranging from intermittent to daily .

These are worth documenting.

They should not be presented as established medical dosing protocols.

Quick Logic Summary

Protocol Question Verdict Is NAD+ essential for cellular energy metabolism?

Yes, very well established Is NAD+ a peptide? No Does administered NAD+ enter human metabolism?

Yes Has IV NAD+ been studied in humans? Yes, but evidence is limited Has IM NAD+ been given to humans in controlled research?

Yes, very early 100 mg data Has SC NAD+ been given to humans in controlled research?

Yes, very early 100 mg data Is 100 mg IM/SC proven effective? No Is 50–200 mg IM 2–3x/week clinically proven?

No, community protocol Is 50–100 mg SC daily clinically proven? No, community protocol Is 50 → 75 → 100 mg titration proven? No, community protocol Does morning dosing work better? Not proven Does fasted dosing work better? Not proven Does pre-workout dosing work better? Not proven Does NAD+ need cycling? No demonstrated reason Does it need a receptor reset? No Is an IV “loading series” clinically established?

Community / clinic convention Does IV automatically mean better tissue delivery?

Not established Is NAD+ the same as NR or NMN? No Is every compounded NAD+ vial equivalent? No Is one universal 14/28-day storage rule valid?

No FDA approved for anti-aging? No

What Does NAD+ Actually Do?

NAD+ does not work like:

liraglutide → GLP-1 receptor or:

T esamorelin → GHRH receptor Instead, NAD+ takes part directly in cellular chemistry .

Simple Version Think of NAD+ as a reusable helper molecule.

It repeatedly:

accepts electrons → carries them → gets recycled while the body turns nutrients into energy .

NAD+ is also used by enzymes involved in:

• DNA repair

• metabolism

• cellular stress responses

• gene regulation

Verdict Its biological role is extremely well established, but NAD+ does not have one single therapeutic receptor target.

NAD+ vs NADH

These are two forms of the same redox system.

NAD+ The oxidized form.

It can:

accept electrons NADH The reduced form.

It:

carries electrons Simple Pathway NAD+ ⇄ NADH The body constantly converts one into the other .

Important Research on NADH should not automatically be used as evidence for:

injected NAD+ They are closely related biologically , but they are not the same administered product.

NAD+ vs NR vs NMN

This is another major source of confusion.

NAD+

The final coenzyme itself.

NR Nicotinamide riboside A precursor the body can use to make NAD+.

NMN Nicotinamide mononucleotide Another NAD-related precursor .

Important A study showing:

oral NR raises NAD+ does not automatically prove:

injecting NAD+ has the same effect or benefit.

Each molecule and route needs its own evidence.

Does Injected NAD+ Go Straight Into Cells?

Not that simply .

NAD+ is a relatively large, charged molecule.

Outside cells, NAD+ can be:

• broken down

• converted

• recycled into other NAD-related compounds

before components are taken up and reused.

The 2019 human IV study showed that infused NAD+ was rapidly removed from the blood and processed into related metabolites.

Better Wording Injected NAD+ enters human metabolism, but it should not be described as going directly from the syringe into every mitochondrion intact.

Verdict Claims like:

“100% bioavailable directly into your mitochondria” are too simplistic and misleading.

Human Half-Life

No Simple Clinically Useful Injection Half-Life Is Established Direct NAD+ is rapidly:

• metabolized

• broken down

• recycled

• converted through multiple pathways

So a statement such as:

“NAD+ has a half-life of X hours, therefore inject every X hours” would be misleading.

Verdict Do not build a community dosing schedule from one plasma half-life number.

How Long Do the Effects Last?

We do not know clearly .

Even if extracellular NAD+ itself is processed quickly:

• downstream metabolites may last longer

• intracellular NAD pools may behave differently

• biological effects may outlast circulating NAD+

We do not have enough direct human injection research to say:

• how long one SC dose “works”

• how long one IM dose “works”

• when another dose is physiologically required

Verdict Unknown

Does It Build Up With Repeated Use?

Possibly at the level of:

• metabolites

• intracellular NAD pools

• related compounds

depending on route and exposure.

But injected NAD+ is heavily processed.

There is not enough evidence to say:

“NAD+ accumulates for X days.”

Verdict The metabolism is complex and clinically useful accumulation data are limited.

Important Research Note

Four different evidence types are commonly mixed together online.

1. Normal NAD+ Biology

This is extremely well established.

NAD+ is essential to normal human metabolism.

2. NAD+ Precursor Research

This includes:

• NR

• NMN

• niacin

• nicotinamide

This research teaches us a great deal about NAD metabolism.

But:

precursor evidence is not automatically NAD+ injection evidence.

3. Direct Human NAD+ Research

This remains relatively small.

It includes:

• IV metabolism studies

• IV tolerability studies

• early preliminary IM / SC / IV-push exposure data

Research at a Glance

Approved-Label Human Evidence

None for NAD+ wellness injections There is no FDA-approved NAD+ injection for:

• energy

• wellness

• anti-aging

Direct Human Clinical Research

Limited but growing Includes:

• direct IV studies

• IV tolerability research

• very early IM / SC human exposure

Human Biological Evidence

Extremely Strong NAD+/NADH chemistry and NAD metabolism are foundational human biochemistry .

Animal / Cell Evidence

Extensive Many aging, metabolic and disease models involve changes in NAD metabolism.

Mechanistic Evidence

Very Strong for natural NAD+ biology Much weaker for predicting:

what happens clinically when extra NAD+ is injected.

Community / Anecdotal Evidence

Common but much weaker A large wellness market exists around injectable NAD+.

The clinical evidence has not caught up with many of the claims.

Overview

NAD+ is one of the most important molecules in human metabolism.

Every cell needs it.

That makes NAD+ marketing sound immediately convincing:

“If NAD+ helps make energy , more NAD+ must give you more energy .”

But the biology is more complicated.

The body tightly controls:

• NAD+ production

• recycling

• breakdown

• transport

• intracellular levels

And NAD+ outside cells is heavily metabolized.

So the important question is not:

Is NAD+ important?

That answer is clearly:

Yes.

The real question is:

Does injecting extra NAD+ improve meaningful health outcomes in people?

For most wellness claims:

we still do not know .

Evidence Strength

Overall Evidence Rating

Extremely strong biology , limited direct-injection evidence Strong Evidence For

• NAD+/NADH chemistry

• cellular energy metabolism

• NAD-dependent enzymes

• direct IV NAD+ metabolism

• route-dependent tolerability

Early Human Evidence For

• 100 mg IM NAD+ short-term exposure

• 100 mg SC NAD+ short-term exposure

• 100 mg IV-push NAD+ short-term exposure

Limited or Unproven For

• anti-aging

• longevity

• fatigue treatment

• athletic enhancement

• fat loss

• cognition

• hangovers

• alcohol detoxification

• GLP-1 fatigue

• long-term 50–200 mg IM protocols

• daily 50–100 mg SC protocols

• loading cycles

• maintenance cycles

Category

Cellular Metabolism / Mitochondrial Energy / Redox Cofactors

Compound

NAD+ Full name:

Nicotinamide Adenine Dinucleotide

Compound T ype

Naturally occurring dinucleotide coenzyme NAD+ is:

• naturally present in cells

• essential for cellular metabolism

• part of the NAD+/NADH redox system

It is not:

• a peptide

• a hormone

• a stimulant

• a GLP-1 agonist

Primary Research Focus

Best Established

• cellular energy metabolism

• redox reactions

• NAD-dependent enzyme biology

• cellular metabolism

Human Direct NAD+ Research

2019 IV Metabolism Study 3 μmol/min for 6 hours 2026 IV Study 500 mg IV on:

4 consecutive days 2026 Preliminary Multi-Route Safety Analysis 100 mg NAD+ by:

• IM

• SC

• IV-push

over:

3 consecutive days

in very small groups.

Important These are:

research exposures not:

approved wellness doses

Research Community

PeptideFox

IM 50–200 mg usually:

2–3x/week SC 50–100 mg per dose

PeptideDosages

50 → 75 → 100 mg SC daily for approximately:

8–16 weeks

Direct Human Research

Minutes to Hours Administered NAD+ enters metabolism quickly .

That does not automatically mean an immediate health benefit.

Several Days Short multi-day studies mainly provide:

tolerability information not evidence of:

• anti-aging

• sustained energy improvement

• better cognition

Weeks to Months There is no strong controlled direct-NAD+ study establishing a predictable wellness-results timeline.

Community-Reported

Same Day Some people report:

• alertness

• energy

• general wellness

after IV or injected NAD+.

Several Weeks Community protocols describe:

• steadier energy

• recovery

• mental clarity

during repeated treatment.

Evidence Warning These remain:

community reports Do not call them:

Expected clinical effects

Human IV Research

Reported infusion effects include:

• nausea

• abdominal discomfort

• other GI symptoms

• increased heart rate

• chest pressure

IM / SC

Controlled human evidence is still extremely limited.

A preliminary 100 mg analysis did not report severe unexpected treatment-related events.

But the route groups were:

very small Local discomfort is also commonly reported in community use.

Contaminated or Poor-Quality Injectable Products

FDA has received reports involving:

• severe chills

• shaking

• vomiting

• fatigue

after compounded NAD+ injections.

Some people required medical treatment.

FDA said the reactions were consistent with:

excessive endotoxin exposure

Important Keep these separate:

Side effects caused by NAD+ itself versus:

reactions caused by contaminated or poorly manufactured injectable products

No Universal FDA-Approved NAD+ Injection Exists

There is no approved reference formulation allowing one universal rule for:

• concentration

• diluent

• sterility period

• expiration after opening

• reconstitution method

FDA Product-Quality Warning

FDA warned compounders against using food-grade NAD+ ingredients for sterile injection products without appropriate processing because of:

• contamination

• endotoxin

• sterility

concerns.

This should remain prominent.

PeptideDosages Community Vial

PeptideDosages describes a:

500 mg lyophilized vial mixed with bacteriostatic water .

Its own community protocol lists approximately:

14 days refrigerated after mixing Important That does not mean:

all NAD+ lasts 14 days after reconstitution.

Different products can have different stability .

Simple Rule Use storage instructions for the exact product or pharmacy formulation.

Regulatory Status

United States

FDA-Approved NAD+ Wellness Injection?

No

Compounded NAD+

Compounded preparations exist.

They are not equivalent to an FDA-approved NAD+ drug .

FDA has specifically raised concerns about:

• ingredient quality

• sterile production

• endotoxin contamination

• regulatory eligibility

for some compounded NAD+ products.

2026 503B Enforcement

A January 2026 FDA warning letter stated that NAD+ did:

not appear on the 503B Bulks List and that products compounded from bulk NAD+ by the cited outsourcing facility did not qualify for the relevant exemptions.

Production Wording NAD+ is not FDA approved as an injectable wellness or anti-aging drug.

Compounded products exist, but FDA has raised both regulatory and sterileproduct-quality concerns.

What Studies Have Found

2019 Human IV Metabolism Study

NAD+ was infused for:

6 hours at:

3 μmol/min Researchers found that blood NAD+ did not simply rise immediately .

Instead, infused NAD+ was rapidly:

• removed from plasma

• metabolized

• converted into related compounds

What This Supports

• administered NAD+ enters human metabolism

• extracellular metabolism is important

• IV delivery does not mean intact NAD+ simply stays in circulation

What It Does Not Support

• anti-aging

• more energy

• fatigue treatment

• cognitive enhancement

2026 IV NAD+ Research

Participants received:

500 mg IV NAD+ for:

4 consecutive days The NAD+ group experienced more:

• GI symptoms

• heart-rate increases

• chest pressure

than the IV NR group.

What This Supports Infusion rate and formulation can strongly affect tolerability .

What It Does Not Support 500 mg as a universally optimal IV NAD+ dose

Dosing evidence

Dose at a Glance

FDA-Approved Dosing

There is no FDA-approved general NAD+ injection protocol There is no FDA-approved NAD+ injection dose for:

• energy

• wellness

• anti-aging

• fatigue

• weight loss

• athletic recovery

Compounded NAD+ products exist, but that is not the same thing as having an FDA-approved NAD+ drug.

Human Research Dosing

2019 IV Metabolism Study

Researchers infused NAD+ at:

3 μmol/min for:

6 hours This was a metabolism and pharmacology study .

It was not designed to establish a wellness dose.

2026 IV T olerability Study

A newer human study used:

500 mg NAD+ IV on:

4 consecutive days Participants receiving NAD+ had more infusion-related symptoms than those receiving IV nicotinamide riboside.

Reported effects included:

• stomach and digestive symptoms

• increased heart rate

• chest pressure

Important This was mainly a tolerability comparison.

It does not prove that:

500 mg is the ideal NAD+ treatment dose.

2026 IM / SC / IV-Push Pilot

A 2026 preliminary safety analysis associated with this research program reported small human groups receiving:

100 mg NAD+ by:

• IM

• SC

• IV-push

on:

3 consecutive days

Important This report is a:

preprint That means it provides useful early human information, but it has not yet gone through the same peer-review process as a published clinical paper .

The participant groups were also very small.

What This Changes We can now say:

There is preliminary controlled human exposure to 100 mg NAD+ by IM and SC injection.

We should not say:

100 mg IM or SC NAD+ is a clinically proven treatment dose.

Evidence Classification Preliminary human safety / tolerability evidence Not:

Established efficacy evidence

Research-Community Dosing

Community protocols are much more developed than the clinical evidence.

PeptideFox

IM Approximately:

50–200 mg per injection commonly:

2–3 times per week during more active use.

Less frequent maintenance schedules are also discussed.

SC Approximately:

50–100 mg per dose Smaller divided injections are often used because SC NAD+ can be uncomfortable or irritating.

Lower starting doses around:

25 mg are also discussed for tolerance testing.

Evidence level Community / practitioner protocol The upper ends of these dose ranges have not been validated by completed human dosefinding trials.

PeptideDosages

PeptideDosages describes:

Week 1: 50 mg SC daily Week 2: 75 mg SC daily Week 3 onward: 100 mg SC daily for approximately:

8–16 weeks Evidence level Community protocol The exact:

50 → 75 → 100 mg dose ladder and:

8–16 week cycle have not been proven by a matching clinical NAD+ efficacy trial.

Frequency at a Glance

Timing at a Glance

Duration / Cycle at a Glance

Protocol Logic Check

Does Daily SC Dosing Make Sense?

PeptideDosages uses:

50 → 75 → 100 mg SC daily There is now preliminary human exposure to:

100 mg SC on three consecutive days.

That means short-term repeated SC use is no longer supported only by anecdotes.

But the early research does not validate:

• 8 weeks

• 12 weeks

• 16 weeks

• permanent 100 mg daily use

• anti-aging benefit

• energy improvement

Verdict 100 mg SC now has very early short-term human tolerability precedent. Long-term daily protocols remain unproven.

Does 2–3 Times Weekly IM Make Sense?

Community protocols commonly use:

50–200 mg IM approximately:

2–3 times weekly The 2026 preliminary analysis gives us initial controlled human experience with:

100 mg IM But it does not validate:

• 200 mg IM

• 2–3x-weekly chronic dosing

• long-term use

• wellness efficacy

Verdict 100 mg IM has very early human safety precedent. The broader community protocol remains unvalidated.

Does Morning Dosing Make Sense?

Some people prefer morning injections because NAD+ is marketed for energy .

There is no clinical evidence showing morning dosing produces better:

• energy

• metabolism

• cognition

• exercise performance

Verdict Community preference

Does Fasted Dosing Make Sense?

There is no good direct-NAD+ evidence showing fasting improves:

• absorption

• cellular uptake

• energy

• mitochondrial effects

• fat loss

Verdict Unproven

Pre-Workout Timing

NAD+ is important for cellular energy metabolism.

That alone does not prove injecting NAD+ before exercise improves performance.

Verdict No established advantage

Does NAD+ Need a Loading Phase?

Some IV clinics use several high-dose infusions over a short period.

Community examples include:

4–5 IV sessions over about 2 weeks No randomized human trial has established that this is the best way to “restore” NAD+ in otherwise healthy adults.

Verdict Clinic / community convention

Does It Need an 8–16 Week Cycle?

Some community SC protocols use:

8–16 weeks There is no known biological event at week:

• 8

• 12

• 16

that means NAD+ must suddenly be stopped.

Verdict Community framework, not a proven biological requirement

Does It Need a Receptor Reset?

No.

NAD+ is not acting like a conventional receptor-stimulating drug.

There is no established:

• NAD receptor reset

• receptor desensitization cycle

• 2–4 week recovery period

Verdict No receptor-reset logic

Dose Escalation / Titration

Starting lower may make practical sense because injected NAD+ can be uncomfortable.

But the specific:

50 → 75 → 100 mg community ladder is not a medically established titration schedule.

Verdict Community titration based on tolerability

Does Route Matter?

IV Most historical direct-NAD+ human research.

IM Very early controlled human exposure now exists at:

100 mg SC Very early controlled human exposure now exists at:

100 mg

Community

All three routes are used.

Verdict The routes should not be treated as interchangeable simply because they contain NAD+.

Different routes may produce different:

• exposure

• discomfort

• metabolism

• tolerability

• dosing needs

IV Infusion Speed Logic

This matters.

In a study using:

500 mg IV NAD+ participants experienced:

• GI symptoms

• increased heart rate

• chest pressure

The NAD+ infusions took much longer than the comparison infusions because symptoms limited how quickly NAD+ could be administered.

What This T ells Us Faster is not necessarily better.

Verdict Infusion speed can strongly affect tolerability .

Do not describe symptoms such as:

• chest pressure

• nausea

• severe discomfort

during rapid infusion as:

“proof the NAD+ is working.”

4. Community / Clinic Protocols

These include:

• 500–1,000 mg IV

• 50–200 mg IM

• 50–100 mg SC

• loading series

• maintenance injections

• 8–16 week cycles

These are useful to document.

They are not equivalent to established clinical dosing.

Direct Human Administration Research

• IV metabolism

• IV tolerability

• early IM / SC tolerability

Common Wellness Claims Not Established

• energy enhancement

• anti-aging

• cognitive enhancement

• fatigue treatment

• addiction detoxification

• weight loss

• athletic performance

Common Research Dose

Community Protocol Comparison

Source Dose Route Frequency Evidence 2019 human study 3 μmol/min IV 6-hour infusion Human metabolism research 2026 IV study 500 mg IV Daily ×4 Human tolerability research 2026 preliminary analysis 100 mg IM / SC / IV-push Daily ×3 Preliminary human safety PeptideFox 50–200 mg IM 2–3x/week Community PeptideFox 50–100 mg SC Variable Community

Source Dose Route Frequency Evidence PeptideDosages 50→75→100 mg SC Daily Community Strongest Conclusion There is:

no validated universal NAD+ injection protocol.

Expected Results Timeline, Expanded

Contraindications

Safety at a Glance

IV NAD+ Can Be Difficult to T olerate

A newer study using:

500 mg IV NAD+ reported symptoms including:

• gastrointestinal discomfort

• increased heart rate

• chest pressure

The NAD+ infusions took considerably longer than the comparison infusions because symptoms limited how quickly they could be given.

Important Infusion speed appears to matter.

That does not mean faster infusion works better .

IM / SC Safety

A 2026 preliminary analysis gives us a small amount of controlled human experience with:

100 mg NAD+ by:

• IM

• SC

• IV-push

over three consecutive days.

No severe unexpected treatment-related event was reported in that small preliminary analysis.

But each route group included only a small number of people.

Meaning This gives us:

early short-term tolerability data not:

established long-term safety

FDA Injectable Product-Quality Warning

This is one of the most important NAD+ safety issues.

FDA has received adverse-event reports after compounded NAD+ injections involving:

• severe chills

• shaking

• vomiting

• fatigue

Some people required medical treatment.

FDA said these reactions were consistent with:

excessive endotoxin exposure and warned that food-grade NAD+ ingredients are not appropriate for sterile drug compounding without proper pharmaceutical processing.

Important Distinction This does not necessarily mean NAD+ itself caused every reaction.

It highlights a separate problem:

Poorly prepared injectable products can cause serious harm even if the active ingredient itself is not the main problem.

Formal Contraindications

No FDA-approved NAD+ injection label exists There is no official FDA contraindication list for injectable NAD+ used for:

• wellness

• energy

• anti-aging

Navaro should not create a formal contraindication list by turning every theoretical concern into an official contraindication.

Important Cautions

Pregnancy / Breastfeeding

There is not enough direct injectable-NAD+ safety evidence.

Classification: Safety unknown.

Significant Cardiovascular Disease

Higher-dose IV NAD+ has been associated with:

• increased heart rate

• chest pressure

• significant infusion discomfort

Classification: Important caution.

Contraindications & Cautions

Formal FDA Contraindications

None established There is no FDA-approved NAD+ wellness injection label.

Important Cautions

Cardiovascular Symptoms During IV Use Chest pressure and increased heart rate have occurred during higher-dose IV NAD+ administration.

Product Quality Sterility and endotoxin control are critical.

Pregnancy / Breastfeeding Direct injection safety is not adequately studied.

Long- T erm IM / SC Use Controlled long-term safety is not established.

2026 IM / SC / IV-Push Preliminary Safety Analysis

A 2026 preliminary analysis reported:

100 mg NAD+ given by:

• IM

• SC

• IV-push

over:

three consecutive days What This Supports We now have:

early controlled human exposure to IM and SC NAD+.

What It Does Not Support

• chronic 100 mg daily treatment

• 200 mg IM protocols

• 8–16 week use

• anti-aging efficacy

• fatigue treatment

• increased mitochondrial function

The groups were small and the analysis was focused mainly on:

short-term safety and tolerability

Corrected ClinicalTrials.gov Section

NCT06919328

The registered study is primarily described as research evaluating injectable:

nicotinamide riboside including absorption and tolerability across routes such as:

• IM

• SC

• IV-push

This study record is useful for documenting the broader human injection-research framework.

It should not be used as the direct source for the specific NAD+ findings involving:

• 100 mg NAD+

• IM NAD+

• SC NAD+

• IV-push NAD+

• three consecutive days of NAD+ administration

Those findings belong to the later:

2026 preliminary safety analysis

Side effects

Reported Side Effects

Compatibility

Stack / Pairing Logic

NAD+ + MOTS-c

They affect different parts of cellular energy metabolism.

Verdict: Could be complementary in theory , but no validated human combination protocol exists.

NAD+ + SS-31 / Elamipretide

NAD+ participates in redox metabolism.

SS-31 affects mitochondrial membrane and cardiolipin biology .

Verdict: Different mechanisms, but the combination is clinically unvalidated.

NAD+ + L-Carnitine

L-Carnitine helps move fatty acids into mitochondria.

NAD+/NADH helps with the chemistry used to extract energy from those fuels.

Verdict: Different but related metabolic roles; no established injected combination protocol.

NAD+ + GLP-1 Drugs

NAD+ is often promoted for fatigue during GLP-1 treatment.

There is no controlled human evidence showing injectable NAD+:

• prevents GLP-1 fatigue

• prevents muscle loss

• improves GLP-1 weight loss

Verdict Different mechanism, but the claimed benefit is unproven

NAD+ + NR / NMN

All of these affect NAD metabolism.

Verdict Biologically related and potentially overlapping in purpose, but their pharmacology is different.

There is no universally proven reason to use all of them together .

Source url

Research Sources

Use clean canonical URLs in production .

1. Grant et al. 2019: Human IV NAD+ Metabolism Evidence type: Human metabolism research Supports:

• direct IV NAD+ administration

• 6-hour infusion

• human NAD+ metabolism

• rapid plasma processing

• NAD-related metabolite changes

https://pubmed.ncbi.nlm.nih.gov/31572171/

2. Reyna et al. 2026: IV NAD+ vs IV Nicotinamide Riboside Evidence type: Human tolerability research Supports:

• 500 mg NAD+ IV

• four consecutive treatment days

• GI symptoms

• increased heart rate

• chest pressure

• slower NAD+ infusion due to tolerability

https://pubmed.ncbi.nlm.nih.gov/41704678/ 3. ClinicalTrials.gov NCT06919328 Evidence type: Registered human injection study Supports:

• injection-route research involving nicotinamide riboside

• IM administration research

• SC administration research

• IV-push administration research

• human injection tolerability framework

It should not be used as the direct source for the 100 mg NAD+ IM/SC/IV-push findings.

https://clinicaltrials.gov/study/NCT06919328 4. Nkrumah-Elie et al. 2026 Preliminary Safety Analysis Evidence type: Human preliminary safety analysis / preprint Supports:

• 100 mg NAD+

• IM NAD+ exposure

• SC NAD+ exposure

• IV-push NAD+ exposure

• administration over three consecutive days

• preliminary short-term tolerability findings

Important This is a:

preprint not a peer-reviewed efficacy trial.

It supports wording such as:

early controlled human exposure or:

preliminary human tolerability evidence

not:

clinically validated NAD+ injection protocol https://www.medrxiv.org/content/10.64898/2026.04.28.26352007v1 5. FDA: Sterile NAD+ Compounding Warning Evidence type: FDA product-quality and safety information Supports:

• food-grade NAD+ concerns

• sterile compounding concerns

• endotoxin risk

• severe chills

• shaking

• vomiting

• fatigue reports

https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-useingredients-suitable-sterile-compounding 6. FDA 2026 GenoGenix Warning Letter Evidence type: FDA regulatory enforcement source Supports:

• 503B regulatory concerns

• bulk NAD+ compounding issue

• endotoxin/product-quality concerns involving NAD+ products

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warningletters/genogenix-llc-718739-01202026 7. PeptideFox: NAD+ Guide Evidence type: Community / practitioner protocols Useful for documenting:

• IM 50–200 mg

• SC 50–100 mg

• 2–3x-weekly IM use

• community IV protocols

• route tolerability

• loading-series practices

https://peptidefox.com/content/nad-guide

8. PeptideDosages: NAD+ 500 mg Vial Evidence type: Community protocol Useful for documenting:

• 50 → 75 → 100 mg SC titration

• daily use

• 8–16 week framework

• community reconstitution

• community storage guidance

https://peptidedosages.com/single-peptide-dosages/nad-500-mg-10ml-vial-dosageprotocol/

Final T akeaway

NAD+ is essential for human cellular metabolism. That part is certain. The benefits of injecting extra NAD+ are much less certain.

The strongest science supports NAD+’s role in:

• energy metabolism

• redox chemistry

• NAD-dependent cellular signaling

Direct human administration research shows that NAD+:

• enters and is processed by human metabolism

• can cause significant infusion-related discomfort at higher IV doses

• now has preliminary controlled human IM and SC exposure data at 100 mg

But we still do not have established clinical evidence supporting one universal:

50–100 mg daily SC or:

50–200 mg IM 2–3 times weekly wellness protocol.

Those remain:

community / practitioner protocols There is also no evidence-based:

• receptor reset

• mandatory cycle

• morning requirement

• fasted requirement

• pre-workout requirement

The most important idea for the page should remain:

NAD+ being essential for cellular energy does not prove that injecting more NAD+ gives a healthy person more energy .

And the important 2026 update is:

IM and SC NAD+ are no longer supported only by anecdotes. A small preliminary analysis has now reported 100 mg NAD+ given by both routes. But that provides early tolerability evidence, not proof of anti-aging, energy, fatigue or metabolic benefits.

Navaro Compounds.pdf, pages 170–210.

Storage

Sterile Product Quality

Contamination and endotoxin exposure are serious risks for poorly prepared injectable products.

Classification: Important product-quality concern.

Formulation / Stability / Sterility

Supplied Navaro reference

Research Sources

Use clean canonical URLs in production .

1. Grant et al. 2019: Human IV NAD+ Metabolism Evidence type: Human metabolism research Supports:

• direct IV NAD+ administration

• 6-hour infusion

• human NAD+ metabolism

• rapid plasma processing

• NAD-related metabolite changes

https://pubmed.ncbi.nlm.nih.gov/31572171/

2. Reyna et al. 2026: IV NAD+ vs IV Nicotinamide Riboside Evidence type: Human tolerability research Supports:

• 500 mg NAD+ IV

• four consecutive treatment days

• GI symptoms

• increased heart rate

• chest pressure

• slower NAD+ infusion due to tolerability

https://pubmed.ncbi.nlm.nih.gov/41704678/ 3. ClinicalTrials.gov NCT06919328 Evidence type: Registered human injection study Supports:

• injection-route research involving nicotinamide riboside

• IM administration research

• SC administration research

• IV-push administration research

• human injection tolerability framework

It should not be used as the direct source for the 100 mg NAD+ IM/SC/IV-push findings.

https://clinicaltrials.gov/study/NCT06919328 4. Nkrumah-Elie et al. 2026 Preliminary Safety Analysis Evidence type: Human preliminary safety analysis / preprint Supports:

• 100 mg NAD+

• IM NAD+ exposure

• SC NAD+ exposure

• IV-push NAD+ exposure

• administration over three consecutive days

• preliminary short-term tolerability findings

Important This is a:

preprint not a peer-reviewed efficacy trial.

It supports wording such as:

early controlled human exposure or:

preliminary human tolerability evidence

not:

clinically validated NAD+ injection protocol https://www.medrxiv.org/content/10.64898/2026.04.28.26352007v1 5. FDA: Sterile NAD+ Compounding Warning Evidence type: FDA product-quality and safety information Supports:

• food-grade NAD+ concerns

• sterile compounding concerns

• endotoxin risk

• severe chills

• shaking

• vomiting

• fatigue reports

https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-useingredients-suitable-sterile-compounding 6. FDA 2026 GenoGenix Warning Letter Evidence type: FDA regulatory enforcement source Supports:

• 503B regulatory concerns

• bulk NAD+ compounding issue

• endotoxin/product-quality concerns involving NAD+ products

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warningletters/genogenix-llc-718739-01202026 7. PeptideFox: NAD+ Guide Evidence type: Community / practitioner protocols Useful for documenting:

• IM 50–200 mg

• SC 50–100 mg

• 2–3x-weekly IM use

• community IV protocols

• route tolerability

• loading-series practices

https://peptidefox.com/content/nad-guide

8. PeptideDosages: NAD+ 500 mg Vial Evidence type: Community protocol Useful for documenting:

• 50 → 75 → 100 mg SC titration

• daily use

• 8–16 week framework

• community reconstitution

• community storage guidance

https://peptidedosages.com/single-peptide-dosages/nad-500-mg-10ml-vial-dosageprotocol/

Final T akeaway

NAD+ is essential for human cellular metabolism. That part is certain. The benefits of injecting extra NAD+ are much less certain.

The strongest science supports NAD+’s role in:

• energy metabolism

• redox chemistry

• NAD-dependent cellular signaling

Direct human administration research shows that NAD+:

• enters and is processed by human metabolism

• can cause significant infusion-related discomfort at higher IV doses

• now has preliminary controlled human IM and SC exposure data at 100 mg

But we still do not have established clinical evidence supporting one universal:

50–100 mg daily SC or:

50–200 mg IM 2–3 times weekly wellness protocol.

Those remain:

community / practitioner protocols There is also no evidence-based:

• receptor reset

• mandatory cycle

• morning requirement

• fasted requirement

• pre-workout requirement

The most important idea for the page should remain:

NAD+ being essential for cellular energy does not prove that injecting more NAD+ gives a healthy person more energy .

And the important 2026 update is:

IM and SC NAD+ are no longer supported only by anecdotes. A small preliminary analysis has now reported 100 mg NAD+ given by both routes. But that provides early tolerability evidence, not proof of anti-aging, energy, fatigue or metabolic benefits.

Navaro Compounds.pdf, pages 170–210.